预约演示
更新于：2025-10-21
Betamethasone/Calcipotriol
卡泊三醇倍他米松
更新于：2025-10-21
概要
基本信息
权益机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2013-06-25), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H40O3 |
InChIKeyLWQQLNNNIPYSNX-UROSTWAQSA-N |
CAS号112965-21-6 |
查看全部结构式(2)
关联
26
项与 卡泊三醇倍他米松 相关的临床试验CTR20251296
卡泊三醇倍他米松软膏生物等效性研究与人体药代动力学对比研究
CTR20243560
卡泊三醇倍他米松软膏（1g：卡泊三醇50μg；倍他米松0.5mg）在中国健康受试者中生物等效性研究
CTRI/2024/07/071444
A Randomized, Phase III, Three-Parallel Arm, Assessor-Blind, Active and Placebo Controlled Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of AKP02G2 Cutaneous Spray versus Enstilar Cutaneous Foam in Subjects with Mild to Moderate Psoriasis. - Nil
100 项与 卡泊三醇倍他米松 相关的临床结果
登录后查看更多信息
100 项与 卡泊三醇倍他米松 相关的转化医学
登录后查看更多信息
100 项与 卡泊三醇倍他米松 相关的专利（医药）
登录后查看更多信息
14
项与 卡泊三醇倍他米松 相关的文献（医药）2022-01-01Contact dermatitis2区 · 医学
Mask‐induced Koebner phenomenon in an inverse psoriatic patient during COVID ‐19 pandemic
2区 · 医学
Article
作者: Chen, Ling ; Sun, Xiao ; Shen, Zhu
We describe a case of mask-induced Koebner phenomenon in an inverse psoriatic patient during the COVID-19 pandemic.A 19-yr-old man developed well-defined erythematous patches covered with scales in both of his ear grooves for 4 mo, which worsened 4 wk ago.Meanwhile, the patient also had lesions on his scalp, belly button, perineum, and axillae.He had a 1-yr history of inverse psoriasis.Before the first onset of psoriasis in the ear grooves, he had worn a mask almost every day, especially when riding on the subway.His lesions in the ear grooves were aggravated after his participation in military training at the university 4 wk ago.The diagnosis of inverse psoriasis in the ear grooves by mask laces was made.He was prescribed topical tacrolimus ointment in the ear grooves and body folds, and calcipotriol betamethasone gel on the scalp.Meanwhile, he was advised to avoid using ear-hook masks.Two weeks later, the skin lesions in the ear grooves turned into pale red patches, and scales disappeared.
2021-09-01Journal of cosmetic dermatology4区 · 医学
Efficacy of topical calcipotriol betamethasone dipropionate as a new adjuvant therapy to follicular unit extraction technique in treatment of stable vitiligo: clinical, dermoscopic and immunohistological study
4区 · 医学
Article
作者: EL‐Deek, Heba E. M. ; Abdel Gaber, Reham M. ; Fathy, Eman ; Kamal, Ahmed ; Abd Elazim, Nagwa E.
Abstract:
Background:
Follicular unit extraction (FUE) grafting is a surgical procedure which provides the vitiliginous patches with undifferentiated stem cells of the hair follicles. It has been postulated that adjuvant therapy enhances the results. This is the first study to assess two different adjuvant therapies vs FUE alone.
Aims:
To study the efficiency of FUE alone or combined with either topical calcipotriol betamethasone dipropionate (CBD) or NB‐UVB phototherapy in cases of nonsegmental stable vitiligo. To assess the role of dermoscopy in monitoring the pattern and degree of repigmentation.
Patients/ Methods:
53 patients with 94 lesions with stable nonsegmental vitiligo were divided into three groups. Group 1 (n = 16) with 30 lesions received FUE alone. Group 2 (n = 18) with 32 lesions received FUE plus topical CBD. Group 3 (n = 19) with 32 lesions received FUE plus NB‐UVB phototherapy. Assessment was done by grades of repigmentation, color match, percent of size reduction, and immunohistochemical evaluation of perilesional CD8+T lymphocytes.
Results:
The fastest onset of repigmentation was observed in both groups 2 and 3 in the second week (16.7%, 10.5%, respectively).Group 2 achieved the best response by all methods of assessment. Perifollicular diffuse repigmentation was the commonest dermoscopic pattern in 60 lesions (63.8%). There was a statistically significant decrease in perilesional CD8+T lymphocytes after 4 months.
Conclusion:
FUE is an effective method of surgical treatment of stable vitiligo, and topical CBD as a new adjuvant therapy is successful in targeting the immunological background of vitiligo. Dermoscopy has an essential role in monitoring the repigmentation response.
2017-03-01Journal of the European Academy of Dermatology and Venereology : JEADV2区 · 医学
Optimal maintenance treatment with calcipotriol/betamethasone dipropionate gel in Korean patients with psoriasis vulgaris: a multicentre randomized, controlled clinical trial
2区 · 医学
Article
作者: Park, C.‐J. ; Kim, K.‐J. ; Youn, S.‐W. ; Lee, J.‐H. ; Choi, J.‐H. ; Kim, N.‐I. ; Choe, Y.‐B. ; Kim, T.‐Y. ; Youn, J.‐I. ; Song, H.‐J.
Abstract:
Background:
There is a lack of response data for topical treatments for psoriasis vulgaris in Asian patients.
Objectives:
To determine the optimal maintenance regimen for topical treatment with calcipotriol monohydrate/betamethasone dipropionate gel in Korean patients with psoriasis vulgaris, by comparing the efficacy of three 8‐week maintenance regimens.
Methods:
This was a multicentre, prospective, randomized, controlled, parallel‐group, open‐label, phase 4 clinical trial, conducted in South Korea. Patients with psoriasis vulgaris on the limbs/trunk received once‐daily treatment with calcipotriol monohydrate (50 μg/g)/betamethasone dipropionate (500 μg/g) gel for 8 weeks (induction phase). Responders (defined as an Investigator's Global Assessment of Disease Severity (IGA) grade of ‘clear’ or ‘almost clear’) were then randomized to receive 8 weeks’ maintenance treatment with Xamiol® gel once daily as needed [pro re nata (PRN Group)], once daily every day (Continuous group), or twice weekly – on Saturday and Sunday (Weekend group). The primary endpoint was the percentage of IGA responders at week 16.
Results:
At the end of the induction phase, 62.18% of patients were IGA responders. At the end of the maintenance phase (week 16), the responder rate was 63.89% for the PRN group, 67.5% for the Continuous group and 31.43% for the Weekend group. The PRN and Continuous groups were statistically superior to the Weekend group (P = 0.0109 and P = 0.0015), but the PRN and Continuous groups did not differ statistically. The incidence of adverse events did not differ significantly between the groups.
Conclusion:
Among Korean patients with psoriasis vulgaris, maintenance treatment with calcipotriol monohydrate/betamethasone dipropionate using a continuous daily regimen or an ‘as needed’ daily regimen provided similar efficacy, whereas a twice‐weekly regimen was significantly less efficacious than either of these regimens.
100 项与 卡泊三醇倍他米松 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 银屑病 | 中国 | 2013-06-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 寻常性银屑病 | 申请上市 | 加拿大 | 2025-07-01 | |
| 银屑病关节炎 | 申请上市 | 加拿大 | 2025-01-01 | |
| 玫瑰痤疮 | 临床2期 | 美国 | 2011-09-01 | |
| 关节炎 | 临床2期 | 德国 | 2009-09-01 | |
| 斑块状银屑病 | 临床2期 | 德国 | 2009-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 遞築簾壓選鹽衊憲範淵(構淵壓衊齋蓋簾選願網) = 0.8%/0.1% vs 7.4% 獵壓鏇願簾鑰構憲鏇鹹 (齋襯壓夢鹹觸簾蓋鏇構 ) 更多 | - | 2022-05-12 | |||
临床2期 | 33 | 廠廠鏇齋艱淵艱遞衊膚 = 築餘廠餘選鏇憲衊選膚 網夢製觸鏇糧窪夢膚觸 (壓願獵憲顧壓願網夢艱, 餘窪鬱獵醖窪壓獵鑰醖 ~ 鬱獵製餘壓鏇蓋網廠積) 更多 | - | 2013-01-07 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用